Key Highlights: Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS...
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies )
Also on site :
- Little Debbie's Surprising New Treat Leaks and Fans Want '15 of Them'
- Evacuations underway in Leander after home explosion
- 6 months of LA-area wildfire recovery through the eyes of the Army Corps colonel on the frontlines